This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Destiny Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Destiny Pharma's revenue and earnings are forecast to decline at 171.4% and 15.5% per annum respectively while EPS is expected to decline by 13.6% per annum.

Anahtar bilgiler

-15.5%

Kazanç büyüme oranı

-13.6%

EPS büyüme oranı

Biotechs kazanç büyümesi34.8%
Gelir büyüme oranı-171.4%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme15 Jul 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

Sep 26
Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

May 26
We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Feb 01
Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Aug 05
Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Apr 16
Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

Feb 11
What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Nov 30
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Kazanç ve Gelir Büyüme Tahminleri

AIM:DEST - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2025N/A-8N/AN/A1
12/31/2024N/A-6-6-52
12/31/20231-6-6-5N/A
9/30/20231-6-5-5N/A
6/30/20231-6-5-5N/A
3/31/20231-6-6-6N/A
12/31/20220-7-6-6N/A
9/30/20220-6-5-5N/A
6/30/20220-6-5-5N/A
3/31/20220-6-5-5N/A
12/31/20210-5-5-5N/A
9/30/20210-5-7-6N/A
6/30/20210-5-9-6N/A
3/31/20210-5-8-6N/A
12/31/20200-5-8-5N/A
9/30/20200-5-6-5N/A
6/30/20200-5-4-4N/A
3/31/20200-5-4-4N/A
12/31/20190-5-5-5N/A
9/30/20190-5-5-5N/A
6/30/2019N/A-5-6-6N/A
3/31/2019N/A-5-5-5N/A
12/31/2018N/A-5-5-5N/A
9/30/2018N/A-5-4-4N/A
6/30/2018N/A-4-3-3N/A
3/31/2018N/A-4-3-3N/A
12/31/2017N/A-3-2-2N/A
9/30/2017N/A-2N/A-2N/A
6/30/2017N/A-2N/A-1N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A-1N/A-1N/A
12/31/2015N/A-1N/A-1N/A
12/31/2014N/A-2N/A-2N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DEST is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: DEST is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: DEST is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: DEST is forecast to have no revenue next year.

Yüksek Büyüme Geliri: DEST is forecast to have no revenue next year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if DEST's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin